The Story: Brookfield Had a Problem Every Owner Envies
By January 2025, Brookfield Asset Management and its partner, Canadian pension giant CDPQ, owned one of the most compelling industrial businesses in the world, and they were stuck.
Clarios International, the Wisconsin-based car battery manufacturer whose products power one in three cars on the road globally, had been a quiet triumph since Brookfield and CDPQ acquired it from Johnson Controls for roughly $13 billion in 2019. Since the acquisition, annual profitability at Clarios had increased by more than $500 million. The company had paid down over $2 billion in debt. Its aftermarket demand (the kind of recurring, replace-every-few-years revenue that debt markets adore) accounted for 80% of total volumes. The business was, in Brookfield’s own words, in exceptional financial condition.
But there was no exit in sight. Clarios had filed for a U.S. IPO back in July 2021. That filing was eventually withdrawn in early January 2025, citing market conditions. A partial stake sale was on the table but not yet ripe. Brookfield had already returned $10 billion in distributions to its LPs across the portfolio in the prior two years, but the Clarios position, representing significant locked-up value, had yet to generate a distribution event.
The question was not whether the business was good. It clearly was. The question was: how do you extract real capital from a great business you still believe in, without selling it?
The answer came from the credit markets.
The Decision: Debt as the Exit That Wasn’t
Brookfield had a structural advantage most operators never get to use: Clarios was so financially strong, and credit markets were so hungry for quality paper, that the debt itself could become the distribution mechanism.
The mechanics were precise. Rather than selling equity (which would have meant inviting new shareholders onto the cap table at a compressed valuation, locking in gains at an inopportune moment, or handing the IPO process over to fickle public markets) Brookfield instead upfinanced Clarios’s balance sheet with a three-tranche debt raise:
- $2.5 billion USD Term Loan B
- €800 million Euro Term Loan B
- $1.2 billion High-Yield Bond
The proceeds funded a $4.5 billion special dividend to existing shareholders, one of the largest dividend recapitalizations ever executed. Post-transaction, Clarios’s gross leverage rose to approximately 6x adjusted EBITDA, up from the more conservative levels the company had maintained after years of debt paydown. But critically: no equity changed hands. No new owners. No board seats conceded. No valuation negotiated under duress.
This is the architecture of the dividend recap. As a capital structure mechanism, it is straightforward: a company borrows against its future cash flows and returns the proceeds to its owners as a dividend. The ownership register doesn’t move. The operating team doesn’t change. The upside on any future sale (IPO, strategic, or secondary) belongs entirely to the same people who built the business.
The strategic logic was equally clean. Brookfield had spent years reducing Clarios’s debt load, proving the business model, and expanding earnings. The market rewarded quality borrowers with historically competitive spreads. Rather than leave that capacity idle while waiting for exit conditions to align, Brookfield converted balance-sheet strength into cash, today, while retaining all of the future value creation still to come.
“The strong demand for Clarios’ debt provided us an opportunity to upfinance its balance sheet to fund a $4.5 billion distribution.”
Brookfield Business Partners Q4 2024 Letter to Unitholders
The Outcome: Liquidity Now, Upside Later
The transaction closed in Q1 2025 and has since been cited by Brookfield as one of its largest recent realizations. BMO analysts covering the stock held their Outperform rating, noting that while it wasn’t the preferred monetization route for all investors, the recap provided genuine LP liquidity while preserving Clarios’s future optionality, including the still-intact potential for tax credits worth multiples of invested capital under U.S. manufacturing incentives.
Consider the counterfactual. Had Brookfield been forced to sell a stake in Clarios in early 2025 (when IPO markets were still volatile and M&A multiples remained compressed) they would have crystallized a valuation that almost certainly underrepresented the full earnings trajectory of the business. Instead, the recap allowed them to:
- Harvest $4.5 billion in cash now, improving IRR and DPI for their fund’s LPs
- Retain 100% of future upside: including any re-rating as rates decline and exit markets reopen
- Maintain operational control with no new equity partners, governance changes, or competing agendas
- Preserve Clarios’s eligibility for advanced manufacturing tax credits tied to U.S. battery production
At the market level, the Clarios deal was not unique in kind, only in scale. Dividend recap issuance in 2024 hit record territory, with loan market issuance for dividend recaps reaching $35.3 billion in the first half of 2024 alone, matching the peak comparable period from 2013. In September 2024, the loan market issued more than $17.4 billion in a single month to back dividend recaps, a record for any single month in U.S. history. By year-end, the full-year total was tracking to challenge 2021’s all-time high of $76 billion.
These aren’t flukes. They are a structural response to a stuck exit environment. With traditional M&A deal value suppressed and IPO windows unreliable, sponsors and operators used debt markets to generate returns that equity markets couldn’t provide.
The Counterpoint: When the Same Tool Becomes a Weapon
The Clarios story is compelling precisely because of what it isn’t: a story about a struggling business being plundered by debt. But that story exists too, and it’s worth confronting directly.
Steward Health Care offers the starkest possible contrast. In 2010, Cerberus Capital Management acquired a group of Massachusetts hospitals from the nonprofit Caritas Christi Health Care system in a leveraged buyout valued at $895 million, putting up only $246 million in cash. In 2016, the system sold its hospital real estate to Medical Properties Trust for $1.25 billion in a sale-leaseback arrangement. Cerberus used those proceeds to finance a $484 million dividend to one of its funds: extracting capital from a health system that would spend the following years hemorrhaging cash.
By 2023, Steward owed $110 million in rent on its Massachusetts hospitals alone. The company had stopped paying many vendors. In May 2024, Steward filed for Chapter 11 bankruptcy, reporting over $9 billion in total liabilities, including $6.6 billion in long-term lease obligations. Five hospitals have permanently closed since the bankruptcy. Tens of thousands of patients lost access to care.
The financial instrument was essentially the same, debt-funded extraction of capital. The outcome was categorically different. Why?
The answer lives in the gap between the two businesses at the moment of leverage:
- Clarios: 80% recurring aftermarket revenue, $500M+ EBITDA growth since acquisition, $2B+ debt already repaid, dominant global market position, and floating-rate demand insulated from economic cycles
- Steward: operationally distressed hospitals, structurally thin margins, rising lease obligations, no durable pricing power, and a business model dependent on community trust rather than contractual revenue
Leverage doesn’t create business quality. It amplifies whatever is already there.
The Lessons: A Framework for Owner-Operators Facing the Same Choice
The dividend recap is one of the most powerful (and most misused) instruments in private capital. Here is how to think about it with clarity.
When a Leveraged Recap Works
The Clarios playbook succeeds when the underlying business meets four conditions: (1) stable, recurring, or contractual cash flows that can predictably service new debt; (2) genuine EBITDA growth that has been proven, not projected; (3) unused debt capacity created through prior paydown or earnings expansion; and (4) a rational reason not to sell now: whether that’s market timing, tax strategy, or belief in remaining upside. The recap monetizes today’s value without foreclosing tomorrow’s.
For middle-market operators (the business that generates $5M–$25M in EBITDA and has no desire to sell to a PE sponsor yet) the same logic applies at smaller scale. According to industry data, lower middle-market leveraged recapitalizations typically close at 3x to 5x EBITDA in total debt, with unitranche all-in pricing in U.S. middle-market transactions broadly ranging around SOFR plus 500 to 650 basis points through 2024–2025. A business generating $8M in EBITDA with no existing debt can realistically access $24M–$40M in new capital, without surrendering a share of equity.
When It Destroys Value
The structure fails when it is used to disguise weakness rather than crystallize strength. The warning signs: leverage is being added while operating metrics are declining; the distribution permanently impairs the business’s ability to reinvest or weather downturns; or the transaction is fundamentally designed to extract founder wealth ahead of a business that cannot organically service new debt. In those cases, the debt doesn’t preserve equity; it cannibalizes it.
The Structural Tailwind You Shouldn’t Ignore
The private credit market reached an estimated $3 trillion in size at the start of 2025, up from $2 trillion in 2020. Direct lending dry powder alone stood at approximately $500 billion in the first half of 2025: near all-time highs. That capital is competing for quality borrowers, which means terms and access have rarely been better for strong operators who know how to use the tool intelligently. The market has never been more prepared to meet a well-constructed recap on favorable terms.
The Owner’s Framework: Four Questions Before You Recap
- Can the business service the new debt from existing free cash flow with meaningful coverage headroom? If the interest burden requires performance to accelerate before it’s covered, the math is already broken.
- Is the reason for not selling today strategic, or is it avoidance? Recaps work when owners have genuine upside conviction, not when they’re deferring a sale they fear won’t clear.
- Does the post-recap capital structure leave room for adversity? A 6x leverage ratio on a global battery company with monopolistic scale is different from 6x on a regional services business with customer concentration.
- Who is the lender, and what are the covenants? The shift toward covenant-lite structures in recent years, with 71% of 2024 dividend recap deals shipping without maintenance covenants, has reduced near-term lender interference but also removed the early-warning systems that once forced operational course-corrections before crises became unmanageable.
Key Insights
- Liquidity ≠ Exit: The Clarios recap demonstrates that owners can generate institutional-scale distributions, $4.5 billion, without selling a single share, diluting ownership, or negotiating with a strategic acquirer. Capital markets, used correctly, are their own exit mechanism.
- Business quality determines outcome, not instrument: The dividend recap is neutral technology. Clarios and Steward Health Care used structurally similar tools. One compounded value; the other collapsed under the weight of debt on a deteriorating asset. The difference was entirely in the underlying business before the lever was pulled.
- Timing arbitrage is real: A founder or sponsor who executes a recap in a strong credit environment (capturing low spreads, high investor appetite, and covenant flexibility) and waits for a better exit window is practicing legitimate financial strategy, not financial engineering. The two are not the same thing.
- The private credit market is a structural enabler: With over $500 billion in direct lending dry powder at near all-time highs as of mid-2025, and deal count flat while average deal size increases, quality borrowers are negotiating from a position of strength. The competition for good paper means better terms, faster execution, and greater structural flexibility for operators who meet the bar.
- The middle market is next: The dividend recap trend that played out at scale in large PE has been moving downstream. Private credit providers are increasingly structuring recaps for founder-owned businesses at 3x–5x EBITDA, giving operators who once thought this playbook was reserved for institutional sponsors access to the same liquidity tools without the equity dilution that comes with selling to PE.
